Who & where

“It’s about turning vision into reality.”

Commercialising ground-breaking research

Our background: Christchurch Heart Institute Upstream Medical Technologies will commercialise a suite of novel biomarkers for cardiac disease diagnosis. These biomarkers were developed at the Christchurch Heart Institute (CHI), a University of Otago Centre of Research Excellence, in Christchurch, New Zealand. Researchers at the CHI were the first in the world to discover fragments of proteins called signal peptides in the blood. (Siriwardena, M (2010) Circulation 122; 255).This discovery has lead to a novel class of biomarkers that can be used in diagnosis of various cardiovascular diseases and clinically associated diseases.

From New Zealand to the world

The discoverers filed their first patent in 2007 and are working closely with us to build a sustainable New Zealand-based company around the diagnostics platform that uses their patented technology.

A highly respected team

The CHI is led by Professor Mark Richards who holds the Heart Foundation of New Zealand’s Chair in Cardiovascular Studies. The Translational Biodiscovery Laboratory within the CHI is led by Associate Professor Chris Pemberton. The researchers have an established publication record in this field spanning over 10 years.

Our Team

Dr Ruth Appleby

Dr Ruth Appleby
CEO

QUALIFICATIONS:
B.Sc (Hons), PhD in Genetics (human)

Strong research, product development and commercialisation background in the life sciences.

Dr Roland Toder

Dr Roland Toder
Executive Director

QUALIFICATIONS:
B.Sc (Hons), PhD, Habilitation (human genetics & anthropology).

Roland has strong technological expertise and broad executive management experience. Roland is Executive Director of Akalpa, Lifescience Consulting Limited, New Zealand and Partner at Life Science Consult, Management Consulting, Germany.

Colin Dawson

Colin Dawson
Chair

Colin has a strong background in life sciences. And he was a founding partner of health consulting and investment banking firm Medicus Capital and the inaugural CEO of Otago Innovation.

David Christensen

David Christensen
Board

David leads the operational team of commercialisation managers at Otago Innovation, the commercialisation vehicle for the University of Otago, New Zealand.

Steve Silvey

Steve Silvey
Board

QUALIFICATIONS:
B.Sc (Hons) Biology, MBA

Steve has strong entrepreneurial experience. Formerly he was CEO of the Upstart Business Incubator, New Zealand.

Assoc Prof Chris Pemberton

Assoc Prof Chris Pemberton
CSO

QUALIFICATIONS:
M.Sc (Hons), PhD

Assoc. Prof Pemberton has 18 years experience in the discovery and validation of circulating protein markers. He is also a senior member of the Christchurch Heart Institute, New Zealand’s premier cardiovascular research group.